Choose a blog

Entegrion gets $1.9 million from Navy

Entegrion, the RTP company that is working on a replacement for fresh frozen blood, has received $1.9 million from the U.S. Office of Naval Research.

The money will be used to further two technologies Entegrion is developing: a fluid that provides a safer and more readily available alternative to blood transfusion and dehydrated plasma, which can be used more easily in combat.

The Food and Drug Administration recently approved Entegrion's plans to begin Phase 1 studies on Resusix, the plasma substitute. The company's vice president Michael Galiger called the transition from preclinical to clinical development an important milestone.

“This advance combined with our military’s demonstrated confidence in our unique abilities to meet their complex requirements clearly establishes our position in the blood therapeutics market," Galiger said in a statement.

Entegrion is already working under a U.S. Department of Defense contract that provides $24 million for two years with the option for another $19.7 million over another two years. 

Entegrion wins Defense contract

Entegrion, an RTP company, working on a replacement for fresh frozen blood plasma, will get an infusion of $43.7 million from the Department of Defense.

Entegrion's Resusix is dehydrated plasma and could be used more easily in combat situations, according to the company.

"Our focus is to offer a safer and more effective alternative for frozen blood plasma, which often is not readily available in austere and remote locations," Joseph DaCorta, Entegrion's chief technology officer, said in a statement.

The Department of Defense's contract calls for it to pay $24 million for a two-year period with an option of $19.7 million for two more years. During that time the company will take the product through its last phase of clinical trials and biological license application.

The company expects to have as many as 15 clinical sites participating in the product's clinical development and plans to begin recruting them next month.

In August, the life sciences company won a $9.84 million contract with the Navy to study the potential of combining two of its products to develop a treatment for the hemorrhaging and shock that accompanies traumatic combat injuries.

Powdered plasma wins 2-year military contract

Tags: .biz | Entegrion | plasma

A Triangle company that develops techniques to stop emergency bleeding won a $8.2 million grant from the U.S. Department of Defense to develop dried plasma for blood transfusions in battlefield and emergency situations.

Entegrion, based in Research Triangle Park, will use the money to continue researching and developing the its experimental plasma product over two years and produce the material in test batches.

The benefit of dried plasma over frozen plasma is that it can be used in emergencies without chilling equipment and thawing, said Mike Galiger, Entegrion's manager for manufacturing and engineering.

Entegrion wins Navy contracts

The U.S. Navy awarded contracts worth up to $6 million to Entegrion, a small Research Triangle Park biotechnology company developing blood-related products to help treat serious injuries.

The contracts will help develop products that can be used for combat injuries such as Stasix, designed to help control internal bleeding.

Entegrion was founded in 2002 based on blood research at UNC-Chapel Hill.

Cars View All
Find a Car
Go
Jobs View All
Find a Job
Go
Homes View All
Find a Home
Go

Want to post a comment?

In order to join the conversation, you must be a member of newsobserver.com. Click here to register or to log in.
Advertisements